



BIO-MEDICINE LTD.
ISO 9001 - 2008 Certified Company
CIN NO. L24110MH1989PLC052251

Date: 10.11.2015

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Fax : 022-22723121/2041/ 1072

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G block,
Bandra-Kurla Complex,
Bandra (E)
Mumbai - 400 051.
Fax : 022-26598237/38

Ref: Scrip Code - 532908

Scrip ID- SHARONBIO

Sub: Submission of Financial Results under Clause 41 of the Listing Agreement.

Dear Sir/Madam,

In compliance of clause 41 of the Listing Agreement, We hereby submit the Audited Financial Results for the quarter and year ended 30th September, 2015 alongwith the Auditors Limited Review Report thereon.

Thanking You.

Yours Faithfully,
For Sharon Bio-Medicine Limited


(Savita Gowda)
Managing Director
DIN : 00042957

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India),
Works II: Plot No. L-6, MIDC, Talaja, Dist-Raigad, Maharashtra (India)
Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.
Tel. :91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

Caring for relationships

**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER
ENDED SEPTEMBER 30, 2015.**

ISO 9001 : 2008 Certified Company
(Rs. in Lacs)

SR. NO.	PARTICULARS	Quarter ended & year to the date			
		As on 30/09/2015	As on 30/06/2015	As on 30/09/2014	30/06/2015 (Audited)
1	Net Sales / Income from Operations	11,299.48	14,195.82	32,491.62	83,395.46
	Total Income	11,299.48	14,195.82	32,491.62	83,395.46
2	Total Expenditure				
	a) (Increase)/Decrease in Stock in Trade	(553.31)	(1,803.85)	(1,849.85)	2,102.68
	b) Consumption of Materials	9,550.67	13,329.67	23,104.69	69,903.89
	c) Purchases of Trading Goods	355.66	510.21	5,529.04	8,843.17
	d) Employees Cost	549.10	362.71	660.28	1,962.87
	e) Depreciation	499.57	553.70	302.42	1,925.93
	f) Other Expenditure	964.73	1,270.99	1,192.34	3,991.89
	Total	11,366.42	14,223.43	28,938.92	88,750.43
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	(66.94)	(27.61)	3,552.70	(5,354.97)
4	Other Income	71.50	119.26	106.28	263.21
5	Profit from Operations before Interest & Exceptional Items (3 + 4)	4.56	91.65	3,658.98	(5,091.76)
6	Interest	1,672.05	4,975.35	1,396.79	9,364.48
7	Profit after Interest but before Exception items (5-6)	(1,667.49)	(4,883.70)	2,262.19	(14,456.24)
8	Exception Items	5,911.38	3,825.24	(139.01)	7,663.80
9	Profit (+)/Loss(-) from Ordinary Activities before tax (7+8)	(7,578.87)	(8,708.94)	2,123.18	(22,120.04)
10	Tax Expenses	-	(466.36)	312.68	(466.36)
11	Net Profit before ordinary activities (8 - 9)	(7,578.87)	(8,242.58)	1,810.50	(22,586.40)
12	Extra Ordinary Items (Net of Tax)	-	-	-	-
13	Net Profit after Taxes (10 - 11)	(7,578.87)	(8,242.58)	1,810.50	(22,586.40)
14	Paid up Equity Share Capital (Face value of Rs.10/- each)	2,378.71	2,378.71	2,111.38	2,378.71
15	Reserves excluding Revaluation Reserves	-	-	33,327.88	9,338.00
16	Earning Per Shares (Before Extra Ordinary Item)				
	i) Basic	(7.18)	(7.81)	1.71	(21.39)
	ii) Diluted E. P. S	(4.92)	(5.35)	1.18	(14.67)
17	Earning Per Shares (After Extra Ordinary Item)				
	i) Basic	(7.18)	(7.81)	1.71	(21.39)
	ii) Diluted E. P. S	(4.92)	(5.35)	1.18	(14.67)

Part -II

SR. NO.	PARTICULARS	Quarter ended & Year to the date			30/06/2015 (Audited)
		As on 30/09/2015	As on 30/06/2015	As on 30/09/2014	
(A)	Aggregate of Public Shareholdings				
	No. of Shares	46,067,652	46,067,652	42,017,020	46,067,652
	Percentage of Shareholdings	38.73%	38.73%	39.80%	38.73%
18	Promoters & promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	4,632,000	4,632,000	5,000,000	4,632,000
	- Percentage of Shares	6.36%	6.36%	7.87%	6.36%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	3.89%	3.89%	4.74%	3.89%
	(as a % of the total share capital of the Company)				
	b) Non-encumbered				
	- Number of Shares	68,236,048	68,236,048	58,551,980	68,236,048
	- Percentage of Shares	93.64%	93.64%	92.13%	93.64%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	57.38%	57.38%	55.46%	57.38%
	(as a % of the total share capital of the Company)				

Notes:-

- The above results for the quarter ended September 30, 2015 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on November 10, 2015
- The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the periods on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds and interest for the current quarter.
- Previous years figures have been regrouped and recast wherever necessary.
- Information on investor complaints for the quarter ended September 30, 2015 (in nos.)

Sr. No	Opening Balance of Complaints	Received during the Quarter	Disposed Off during the Quarter	Closing Balance
1	NIL	3	3	NIL

By order of the Board
For Sharon Bio-Medicine Ltd.

Savita Gowda
Managing Director.

Place : Mumbai.
Date : 10.11.2015

Office Add. : Plot No: 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West) Mumbai - 400 053
Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com
CIN NO. L24110MH1989PLC052251

www.sharonbio.com

Caring for relationships

CA. S. C. Agrawal

B. Com., (Hons.) L.L.B., F.C.A., DISA (ICAI)



Shyam C. Agrawal & Co.

Chartered Accountants

14, Nityanand Nagar No. 2,
Opp. Bank of Maharashtra,
Near Sanjeevani Hospital, Sahar Road,
Andheri (E), Mumbai - 400 069.
Tel. : (O) 2684 0916 • Tele Fax : 2683 5699
E-mail : shyam31774@yahoo.com
Mobile : 98200-52168

REVIEW REPORT

We have reviewed the accompanying statement of Unaudited financial results of **M/s. Sharon Bio-Medicine Ltd.**, for the quarter ended on **30th September, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies Act (Accounting Standards) Rules, 2006 as per section 211 (3C) of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shyam C. Agrawal & Co.
Chartered Accountants


Shyam Agrawal
Proprietor



Date: 10/11/2015

Place : Mumbai